➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKinsey
Johnson and Johnson
Mallinckrodt
McKesson

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LONAFARNIB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lonafarnib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003956 Combination Chemotherapy in Treating Patients With Advanced Cancer Completed National Cancer Institute (NCI) Phase 1 1999-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH 66336, fluorouracil, and leucovorin in treating patients who have advanced cancer.
NCT00003956 Combination Chemotherapy in Treating Patients With Advanced Cancer Completed Memorial Sloan Kettering Cancer Center Phase 1 1999-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH 66336, fluorouracil, and leucovorin in treating patients who have advanced cancer.
NCT00005030 SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver Withdrawn National Cancer Institute (NCI) Phase 1 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to compare the effectiveness of different doses of SCH 66336 before surgery in treating patients who have colorectal cancer that has metastasized to the liver.
NCT00005030 SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver Withdrawn M.D. Anderson Cancer Center Phase 1 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to compare the effectiveness of different doses of SCH 66336 before surgery in treating patients who have colorectal cancer that has metastasized to the liver.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lonafarnib

Condition Name

Condition Name for Lonafarnib
Intervention Trials
Progeria 4
Breast Cancer 4
Hepatitis D 3
Chronic Hepatitis D Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lonafarnib
Intervention Trials
Hepatitis 8
Hepatitis D 8
Hepatitis D, Chronic 6
Progeria 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lonafarnib

Trials by Country

Trials by Country for Lonafarnib
Location Trials
United States 24
Turkey 2
Netherlands 2
France 2
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lonafarnib
Location Trials
Texas 5
Massachusetts 5
Maryland 3
Ohio 1
Indiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lonafarnib

Clinical Trial Phase

Clinical Trial Phase for Lonafarnib
Clinical Trial Phase Trials
Phase 3 3
Phase 2 16
Phase 1/Phase 2 2
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lonafarnib
Clinical Trial Phase Trials
Completed 11
Terminated 8
Recruiting 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lonafarnib

Sponsor Name

Sponsor Name for Lonafarnib
Sponsor Trials
Schering-Plough 7
National Cancer Institute (NCI) 6
M.D. Anderson Cancer Center 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lonafarnib
Sponsor Trials
Other 24
Industry 18
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.